Base de dados : MEDLINE
Pesquisa : E02.815.639.200.500 [Categoria DeCS]
Referências encontradas : 223 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 23 ir para página                         

  1 / 223 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29178983
[Au] Autor:Picardi C; Perret I; Miralbell R; Zilli T
[Ad] Endereço:Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
[Ti] Título:Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?
[So] Source:Cancer Treat Rev;62:91-96, 2018 Jan.
[Is] ISSN:1532-1967
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Postoperative external beam radiation therapy (EBRT) is a validated treatment option in the adjuvant setting for prostate cancer patients with aggressive pathological features following radical prostatectomy (RP) or as salvage modality in patients with biochemical recurrence after RP. Contemporary randomized phase III trials have provided evidence for using hypofractionation in the definitive treatment setting as an alternative to standard fractionated regimens. Biomathematical modeling for prostate cancer fractionated EBRT associated with widely available refined treatment delivery techniques such as volumetric modulated-arc therapy with image-guided RT may improve the therapeutic ratio. Nevertheless, the role of hypofractionation in the postoperative setting still remains investigational. In this systematic review of the literature we reviewed the role of hypofractionation for postoperative EBRT in the adjuvant or salvage setting in prostate cancer patients previously treated by RP. A favorable acute toxicity profile with, at least, as good biochemical control rates with hypofractionation has been suggested. And yet conflicting results have been reported concerning long-term genitourinary late toxicity. Prospective studies are eagerly awaited to assess the role of hypofractionation in the postoperative setting.
[Mh] Termos MeSH primário: Prostatectomia
Neoplasias da Próstata/radioterapia
Radioterapia Adjuvante/métodos
[Mh] Termos MeSH secundário: Radioterapia Hipofracionada
Seres Humanos
Masculino
Radioterapia Guiada por Imagem
Radioterapia de Intensidade Modulada
Terapia de Salvação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  2 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29059428
[Au] Autor:Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
[Ad] Endereço:Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL; Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ; The University of Texas Health Science Center at Houston School of Public Health, Houston, TX; The University of Tex
[Ti] Título:Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
[So] Source:J Natl Cancer Inst;109(11), 2017 Nov 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Early-stage breast cancer is among the most prevalent and costly malignancies treated in the American health care system. Adjuvant radiotherapy after lumpectomy represents a substantial portion of breast cancer expenditures. The relative value of novel radiotherapeutic approaches such as intraoperative radiotherapy (IORT) and hypofractionated whole breast irradiation (HF-WBI) compared with conventionally fractionated whole breast irradiation (CF-WBI) is unknown. Therefore, we used prospectively collected outcomes from randomized clinical trials (RCTs) to compare the cost-effectiveness of these approaches. Methods: We constructed a decision-analytic model that followed women who were treated with lumpectomy for early-stage breast cancer. Recurrence, mortality, complication rates, and utilities (five-year radiation-associated quality of life scores), were extracted from RCTs. Costs were based on Medicare reimbursement rates. Cost-effectiveness from societal and health care sector perspectives was estimated considering two scenarios-the first assumes that radiation-associated disutility persists five years after treatment, and the second assumes that disutility discontinues. Lifetime outcomes were summarized using incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses evaluated the robustness of the results. Results: HF-WBI dominated CF-WBI (ie, resulted in higher quality-adjusted life-years [QALYs] and lower cost) in all scenarios. HF-WBI also had a greater likelihood of cost-effectiveness compared with IORT; under a societal perspective that assumes that radiation-associated disutility persists, HF-WBI results in an ICER of $17 024 per QALY compared with IORT with a probability of cost-effectiveness of 80% at the $100 000 per QALY willingness-to-pay threshold. If radiation-associated disutility is assumed to discontinue, the ICER is lower ($11 461/QALY), resulting in an even higher (83%) probability of relative cost-effectiveness. The ICER was most sensitive to the probability of metastasis and treatment cost. Conclusions: For women with early-stage breast cancer requiring adjuvant radiotherapy, HF-WBI is cost-effective compared with CF-WBI and IORT.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Neoplasias da Mama/radioterapia
Análise Custo-Benefício
Anos de Vida Ajustados por Qualidade de Vida
[Mh] Termos MeSH secundário: Idoso
Neoplasias da Mama/cirurgia
Radioterapia Hipofracionada
Feminino
Seres Humanos
Cuidados Intraoperatórios
Cadeias de Markov
Mastectomia Segmentar
Meia-Idade
Estadiamento de Neoplasias
Qualidade de Vida
Radioterapia/economia
Radioterapia Adjuvante/economia
Ensaios Clínicos Controlados Aleatórios como Assunto
Sensibilidade e Especificidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171024
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx068


  3 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982908
[Au] Autor:Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
[Ad] Endereço:Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan dshimizu@koto.kpu-m.ac.jp.
[Ti] Título:Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
[So] Source:Anticancer Res;37(10):5829-5835, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: We report the long-term tumor control and toxicity outcomes of patients undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate cancer. PATIENTS AND METHODS: We examined the cases of 138 consecutive patients with stage T1-T3 prostate cancer that were treated with IG-IMRT from June 2007 to July 2009. The median follow-up time was 79 months (range=31-96 months). The planning target volume received a dose of 72.6-74.8 Gy in 33-34 fractions (2.2 Gy/fraction). Megavoltage computed tomographic (CT) scans were performed before each treatment and corrected to the registered positions on the planning CT scans using prostate soft-tissue matching. RESULTS: The 5-year biochemical and clinical relapse-free survival rates were 95% for the low-risk group, 92% for the intermediate-risk group, and 77% for the high-risk group. The 5-year incidence rates of grade 2 and 3 late gastrointestinal toxicities were 6.3% and 3.1%, respectively, and those of grade 2 and 3 late genitourinary toxicities were 7.9% and 0%, respectively. Multivariate analysis indicated that T-stage is a prognostic factor for biochemical relapse-free survival rates. CONCLUSION: This report involved the longest followed-up cohort of patients to have received hypofractionated (2.2 Gy) soft tissue-matched IG-IMRT using tomotherapy. The findings of this study indicate that hypofractionated IMRT is well tolerated and is associated with good long-term tumor-control outcomes in patients with localized prostate cancer.
[Mh] Termos MeSH primário: Adenocarcinoma/radioterapia
Radioterapia Hipofracionada
Neoplasias da Próstata/radioterapia
Radioterapia Guiada por Imagem/métodos
Radioterapia de Intensidade Modulada/métodos
[Mh] Termos MeSH secundário: Adenocarcinoma/diagnóstico por imagem
Adenocarcinoma/patologia
Intervalo Livre de Doença
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Análise Multivariada
Estadiamento de Neoplasias
Valor Preditivo dos Testes
Modelos de Riscos Proporcionais
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/patologia
Lesões por Radiação/etiologia
Interpretação de Imagem Radiográfica Assistida por Computador
Radioterapia Guiada por Imagem/efeitos adversos
Radioterapia de Intensidade Modulada/efeitos adversos
Fatores de Risco
Fatores de Tempo
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  4 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982907
[Au] Autor:Macchia G; Siepe G; Capocaccia I; Nguyen NP; Schiavina R; Cammelli S; Guerri S; Arcelli A; Buwenge M; Ntreta M; Cilla S; Valentini V; Deodato F; Morganti AG
[Ad] Endereço:Radiotherapy Unit, Giovanni Paolo II, Sacred Heart Catholic University, Campobasso, Italy.
[Ti] Título:Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study.
[So] Source:Anticancer Res;37(10):5821-5828, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories. RESULTS: Median follow-up was 30 months. Only two patients (1.6%) developed grade 3 or more acute toxicity: one grade 3 skin toxicity (0.8%) and one grade 4 genitourinary toxicity (0.8%). Grade 2 acute gastrointestinal and genitourinary toxicity was recorded in 24.2% and 17.7% of patients, respectively. Five-year grade 2 or more gastrointestinal and genitourinary toxicity was 1.1% and 7.3%, respectively. Five-year biochemical relapse-free survival was 86.5%. CONCLUSION: After RP, hypofractionated IMRT-SIB demonstrated a favorable toxicity profile and encouraging results in terms of relapse-free survival.
[Mh] Termos MeSH primário: Radioterapia Hipofracionada
Prostatectomia
Neoplasias da Próstata/terapia
Radioterapia de Intensidade Modulada/métodos
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/uso terapêutico
Quimiorradioterapia Adjuvante
Intervalo Livre de Doença
Seres Humanos
Calicreínas/sangue
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Estudos Prospectivos
Antígeno Prostático Específico/sangue
Prostatectomia/efeitos adversos
Neoplasias da Próstata/sangue
Neoplasias da Próstata/patologia
Radioterapia de Intensidade Modulada/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  5 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28871981
[Au] Autor:Modiri A; Sabouri P; Gu X; Timmerman R; Sawant A
[Ad] Endereço:Department of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, Maryland. Electronic address: amodiri@som.umaryland.edu.
[Ti] Título:Inversed-Planned Respiratory Phase Gating in Lung Conformal Radiation Therapy.
[So] Source:Int J Radiat Oncol Biol Phys;99(2):317-324, 2017 Oct 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess whether the optimal gating window for each beam during lung radiation therapy with respiratory gating will be dependent on a variety of patient-specific factors, such as tumor size and location and the extent of relative tumor and organ motion. METHODS AND MATERIALS: To create optimal gating treatment plans, we started from an optimized clinical plan, created a plan per respiratory phase using the same beam arrangements, and used an inverse planning optimization approach to determine the optimal gating window for each beam and optimal beam weights (ie, monitor units). Two pieces of information were used for optimization: (1) the state of the anatomy at each phase, extracted from 4-dimensional computed tomography scans; and (2) the time spent in each state, estimated from a 2-minute monitoring of the patient's breathing motion. We retrospectively studied 15 lung cancer patients clinically treated by hypofractionated conformal radiation therapy, for whom 45 to 60 Gy was administered over 3 to 15 fractions using 7 to 13 beams. Mean gross tumor volume and respiratory-induced tumor motion were 82.5 cm and 1.0 cm, respectively. RESULTS: Although patients spent most of their respiratory cycle in end-exhalation (EE), our optimal gating plans used EE for only 34% of the beams. Using optimal gating, maximum and mean doses to the esophagus, heart, and spinal cord were reduced by an average of 15% to 26%, and the beam-on times were reduced by an average of 23% compared with equivalent single-phase EE gated plans (P<.034, paired 2-tailed t test). CONCLUSIONS: We introduce a personalized respiratory-gating technique in which inverse planning optimization is used to determine patient- and beam-specific gating phases toward enhancing dosimetric quality of radiation therapy treatment plans.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/radioterapia
Neoplasias Pulmonares/radioterapia
Planejamento da Radioterapia Assistida por Computador/métodos
Radioterapia Conformacional/métodos
Radioterapia de Intensidade Modulada/métodos
Técnicas de Imagem de Sincronização Respiratória
[Mh] Termos MeSH secundário: Algoritmos
Carcinoma Pulmonar de Células não Pequenas/diagnóstico por imagem
Radioterapia Hipofracionada
Esôfago/diagnóstico por imagem
Expiração
Tomografia Computadorizada Quadridimensional
Coração/diagnóstico por imagem
Seres Humanos
Pulmão/diagnóstico por imagem
Neoplasias Pulmonares/diagnóstico por imagem
Movimento
Órgãos em Risco/diagnóstico por imagem
Estudos Retrospectivos
Medula Espinal/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  6 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28870792
[Au] Autor:Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
[Ad] Endereço:Department of Neurological Surgery, University of California, San Francisco, San Francisco, California.
[Ti] Título:Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
[So] Source:Int J Radiat Oncol Biol Phys;99(4):797-804, 2017 Nov 15.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To establish the maximum tolerated dose of a 3-fraction hypofractionated stereotactic reirradiation schedule when delivered with concomitant bevacizumab to treat recurrent high-grade gliomas. METHODS AND MATERIALS: Patients with recurrent high-grade glioma with Karnofsky performance status ≥60, history of standard fractionated initial radiation, tumor volume at recurrence ≤40 cm , and absence of brainstem or corpus callosum involvement were eligible. A standard 3+3 phase 1 dose escalation trial design was utilized, with dose-limiting toxicities defined as any grade 3 to 5 toxicities possibly, probably, or definitely related to radiation. Bevacizumab was given at a dose of 10 mg/kg every 2 weeks. Hypofractionated stereotactic reirradiation was initiated after 2 bevacizumab doses, delivered in 3 fractions every other day, starting at 9 Gy per fraction. RESULTS: A total of 3 patients were enrolled at the 9 Gy × 3 dose level cohort, 5 in the 10 Gy × 3 cohort, and 7 in the 11 Gy × 3 cohort. One dose-limiting toxicity of grade 3 fatigue and cognitive deterioration possibly related to hypofractionated stereotactic reirradiation was observed in the 11 Gy × 3 cohort, and this dose was declared the maximum tolerated dose in combination with bevacizumab. Although no symptomatic radionecrosis was observed, substantial treatment-related effects and necrosis were observed in resected specimens. The intent-to-treat median overall survival was 13 months. CONCLUSIONS: Reirradiation using a 3-fraction schedule with bevacizumab support is feasible and reasonably well tolerated. Dose-escalation was possible up to 11 Gy × 3, which achieves a near doubling in the delivered biological equivalent dose to normal brain, in comparison with our previous 6 Gy × 5 schedule. Promising overall survival warrants further investigation.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/administração & dosagem
Astrocitoma/radioterapia
Bevacizumab/administração & dosagem
Neoplasias Encefálicas/radioterapia
Glioblastoma/radioterapia
Recidiva Local de Neoplasia/radioterapia
Radiocirurgia/métodos
[Mh] Termos MeSH secundário: Idoso
Astrocitoma/tratamento farmacológico
Astrocitoma/mortalidade
Astrocitoma/patologia
Encéfalo/efeitos da radiação
Neoplasias Encefálicas/tratamento farmacológico
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/patologia
Radioterapia Hipofracionada
Feminino
Glioblastoma/tratamento farmacológico
Glioblastoma/mortalidade
Glioblastoma/patologia
Seres Humanos
Análise de Intenção de Tratamento
Avaliação de Estado de Karnofsky
Masculino
Dose Máxima Tolerável
Meia-Idade
Recidiva Local de Neoplasia/tratamento farmacológico
Recidiva Local de Neoplasia/mortalidade
Recidiva Local de Neoplasia/patologia
Órgãos em Risco/efeitos da radiação
Estudos Prospectivos
Reirradiação
Carga Tumoral
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 2S9ZZM9Q9V (Bevacizumab)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  7 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28870788
[Au] Autor:Zawaski JA; Sabek OM; Voicu H; Eastwood Leung HC; Gaber MW
[Ad] Endereço:Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
[Ti] Título:Effect of Brain Tumor Presence During Radiation on Tissue Toxicity: Transcriptomic and Metabolic Changes.
[So] Source:Int J Radiat Oncol Biol Phys;99(4):983-993, 2017 Nov 15.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Radiation therapy (RT) causes functional and transcriptomic changes in the brain; however, most studies have been carried out in normal rodent brains. Here, the long-term effect of irradiation and tumor presence during radiation was investigated. METHODS AND MATERIALS: Male Wistar rats ∼7 weeks old were divided into 3 groups: sham implant, RT+sham implant, and RT+tumor implant (C6 glioma). Hypofractionated irradiation (8 or 6 Gy/day for 5 days) was localized to a 1-cm strip of cranium starting 5 days after implantation, resulting in complete tumor regression and prolonged survival. Biopsy of tissue was performed in the implant area 65 days after implantation. RNA was hybridized to GeneChip Rat Exon 1.0 ST array. Data were analyzed using significant analysis of microarrays and ingenuity pathway analysis. H magnetic resonance spectroscopy ( H-MRS) imaging was performed in the implantation site 65 to 70 days after implantation using a 9.4 T Biospec magnetic resonance imaging scanner with a quadrature rat brain array. Immunohistochemical staining for astrogliosis, HMG-CoA synthase 2, γ-aminobutyric acid (GABA) and taurine was performed at ∼65 days after implantation. RESULTS: Eighty-four genes had a false discovery rate <3.5%. We compared RT+tumor implant with RT+sham implant animals. The tumor presence affected networks associated with cancer/cell morphology/tissue morphology. H-MRS showed significant reduction in taurine levels (P<.04) at the implantation site in both groups. However, the RT+tumor group also showed significant increase in levels of neurotransmitter GABA (P=.02). Hippocampal taurine levels were only significantly reduced in the RT+tumor group (P=.03). HMG-CoA synthase 2, GABA and taurine levels were confirmed using staining. Glial fibrillary acidic protein staining demonstrated a significant increase in inflammation that was heightened in the RT+tumor group. CONCLUSIONS: Our data indicate that tumor presence during radiation significantly affects long-term functional transcriptomics landscape and neurotransmitter levels at the tumor implantation site/normal tissue, accompanied by increased inflammation (astrogliosis).
[Mh] Termos MeSH primário: Neoplasias Encefálicas/radioterapia
Encéfalo/efeitos da radiação
Glioma/radioterapia
Neurotransmissores/análise
Lesões Experimentais por Radiação/metabolismo
[Mh] Termos MeSH secundário: Aloenxertos
Animais
Biópsia
Encéfalo/metabolismo
Encéfalo/patologia
Neoplasias Encefálicas/química
Neoplasias Encefálicas/patologia
Radioterapia Hipofracionada
Perfilação da Expressão Gênica
Glioma/química
Glioma/patologia
Gliose/metabolismo
Gliose/patologia
Hipocampo/química
Hipocampo/patologia
Hipocampo/efeitos da radiação
Hidroximetilglutaril-CoA Sintase/análise
Imagem por Ressonância Magnética/métodos
Espectroscopia de Ressonância Magnética
Masculino
Transplante de Neoplasias
Neurotransmissores/metabolismo
Lesões Experimentais por Radiação/patologia
Ratos
Ratos Wistar
Taurina/análise
Fatores de Tempo
Análise Serial de Tecidos/métodos
Ácido gama-Aminobutírico/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neurotransmitter Agents); 1EQV5MLY3D (Taurine); 56-12-2 (gamma-Aminobutyric Acid); EC 2.3.3.10 (Hydroxymethylglutaryl-CoA Synthase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  8 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28847464
[Au] Autor:Cosset JM
[Ad] Endereço:GIE Charlebourg, groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France. Electronic address: jean-marc.cosset@amethyst-radiotherapy.com.
[Ti] Título:[Hypofractionated irradiation of prostate cancer: What is the radiobiological understanding in 2017?]
[Ti] Título:Irradiation hypofractionnée du cancer de prostate : quelles connaissances radiobiologiques en 2017 ?.
[So] Source:Cancer Radiother;21(6-7):447-453, 2017 Oct.
[Is] ISSN:1769-6658
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:For prostate cancer, hypofractionation has been based since 1999 on radiobiological data, which calculated a very low alpha/beta ratio (1.2 to 1.5Gy). This suggested that a better local control could be obtained, without any toxicity increase. Consequently, two types of hypofractionated schemes were proposed: "moderate" hypofractionation, with fractions of 2.5 to 4Gy, and "extreme" hypofractionation, utilizing stereotactic techniques, with fractions of 7 to 10Gy. For moderate hypofractionation, the linear-quadratic (LQ) model has been used to calculate the equivalent doses of the new protocols. The available trials have often shown a "non-inferiority", but no advantage, while the equivalent doses calculated for the hypofractionated arms were sometimes very superior to the doses of the conventional arms. This finding could suggest either an alpha/beta ratio lower than previously calculated, or a negative impact of other radiobiological parameters, which had not been taken into account. For "extreme" hypofractionation, the use of the LQ model is discussed for high dose fractions. Moreover, a number of radiobiological questions are still pending. The reduced overall irradiation time could be either a positive point (better local control) or a negative one (reduced reoxygenation). The prolonged duration of the fractions could lead to a decrease of efficacy (because allowing for reparation of sublethal lesions). Finally, the impact of the large fractions on the microenvironment and/or immunity remains discussed. The reported series appear to show encouraging short to mid-term results, but the results of randomized trials are still awaited. Today, it seems reasonable to only propose those extreme hypofractionated schemes to well-selected patients, treating small volumes with high-level stereotactic techniques.
[Mh] Termos MeSH primário: Radioterapia Hipofracionada
Neoplasias da Próstata/radioterapia
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto
Seres Humanos
Masculino
Radiobiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE


  9 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28721883
[Au] Autor:Stokes WA; Abbott D; Phan A; Raben D; Lanning RM; Karam SD
[Ad] Endereço:Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
[Ti] Título:Patterns of Care for Patients With Early-Stage Glottic Cancer Undergoing Definitive Radiation Therapy: A National Cancer Database Analysis.
[So] Source:Int J Radiat Oncol Biol Phys;98(5):1014-1021, 2017 Aug 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To characterize practice patterns, including temporal trends, in fractionation schedules among patients in the United States undergoing definitive radiation therapy for early-stage glottic cancer and to compare overall survival outcomes between fractionation schedules. METHODS AND MATERIALS: We queried the National Cancer Database for patients with TisN0M0, T1N0M0, or T2N0M0 squamous cell carcinoma of the glottic larynx diagnosed between 2004 and 2012 and undergoing definitive radiation therapy. Dose per fraction was calculated to define cohorts undergoing conventional fractionation (CFxn) and hypofractionation (HFxn). Logistic regression was performed to identify predictors of receiving HFxn, and Cox regression was used to determine predictors of death. One-to-one propensity score matching was then used to compare survival between fractionation schedules. RESULTS: The study included 10,539 patients, with 6576 undergoing CFxn and 3963 undergoing HFxn. Patients with T1 disease comprised a majority of each cohort. Use of HFxn increased significantly over the period studied (P<.001), but even in the final year, nearly one-half of patients continued to receive CFxn. Receipt of HFxn was also independently associated with higher income and facility types other than community cancer programs on logistic regression. On multivariate Cox regression, HFxn was associated with improved survival (hazard ratio [HR] for death, 0.90; 95% confidence interval [CI], 0.83-0.97; P=.008), a finding redemonstrated on univariate Cox regression among a well-matched cohort after propensity score matching (HR, 0.88; 95% CI, 0.80-0.96; P=.003). Subgroup Cox multivariate analysis demonstrated a significant survival advantage with HFxn among patients with T1 disease (HR, 0.90; 95% CI, 0.81-0.99; P=.042) but a nonsignificant benefit among those with Tis (HR, 0.86; 95% CI, 0.57-1.30; P=.472) or T2 (HR, 0.88; 95% CI, 0.76-1.02; P=.099) disease. CONCLUSIONS: Use of HFxn is increasing and is associated with improved survival over CFxn. Our findings support the broadened use of HFxn for patients with early-stage glottic cancer undergoing definitive radiation therapy.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/mortalidade
Carcinoma de Células Escamosas/radioterapia
Radioterapia Hipofracionada
Neoplasias Laríngeas/mortalidade
Neoplasias Laríngeas/radioterapia
[Mh] Termos MeSH secundário: Idoso
Carcinoma de Células Escamosas/patologia
Grupos de Populações Continentais
Bases de Dados Factuais/estatística & dados numéricos
Fracionamento de Dose
Feminino
Glote
Acesso aos Serviços de Saúde
Seres Humanos
Cobertura do Seguro/estatística & dados numéricos
Estimativa de Kaplan-Meier
Neoplasias Laríngeas/patologia
Modelos Logísticos
Masculino
Meia-Idade
Estadiamento de Neoplasias
Pontuação de Propensão
Modelos de Riscos Proporcionais
Fatores Socioeconômicos
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE


  10 / 223 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686531
[Au] Autor:Stankevicius V; Vasauskas G; Rynkeviciene R; Venius J; Pasukoniene V; Aleknavicius E; Suziedelis K
[Ad] Endereço:a National Cancer Institute, Vilnius, Lithuania.
[Ti] Título:Microenvironment and Dose-Delivery-Dependent Response after Exposure to Ionizing Radiation in Human Colorectal Cancer Cell Lines.
[So] Source:Radiat Res;188(3):291-302, 2017 Sep.
[Is] ISSN:1938-5404
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A significant body of knowledge about radiobiology is based on studies of single dose cellular irradiation, despite the fact that conventional clinical applications using dose fractionation. In addition, cellular radiation response strongly depends on cell-cell and cell-extracellular matrix (ECM) interactions, which are poorly established in cancer cells grown under standard 2D cell culture conditions. In this study, we investigated the response of human colorectal carcinoma (CRC) DLD1 and HT29 cell lines, bearing distinct p53 mutations, to a single 2 or 10 Gy dose or fractionated 5 × 2 Gy doses of radiation using global transcriptomics analysis. To examine cellular response to radiation in a cell-ECM-interaction-dependent manner, CRC cells were grown under laminin-rich ECM 3D cell culture conditions. Microarray data analysis revealed that, overall, a total of 1,573 and 935 genes were differentially expressed (fold change >1.5; P < 0.05) in DLD1 and HT29 cells, respectively, at 4 h postirradiation. However, compared to a single dose of radiation, fractionated doses resulted in significantly different transcriptomic response in both CRC cell lines. Furthermore, pathway enrichment analysis indicated that p53 pathway and cell cycle/DNA damage repair or immune response functional categories were most significantly altered in DLD1 or HT29 cells, respectively, after fractionated irradiations. Novel observations of radiation-response-mediated activation of pro-survival pathways in CRC cells grown under lr-ECM 3D cell culture conditions using fractionated doses provide new directions for the development of more efficient radiotherapy strategies. Our results also indicated that cell line specific radiation response with or without activation of the conventional p53 pathway is ECM dependent, suggesting that the ECM is a key component in cellular radiation response.
[Mh] Termos MeSH primário: Sobrevivência Celular/efeitos da radiação
Neoplasias Colorretais/metabolismo
Neoplasias Colorretais/radioterapia
Radioterapia Hipofracionada
Matriz Extracelular/efeitos da radiação
Microambiente Tumoral/efeitos da radiação
[Mh] Termos MeSH secundário: Matriz Extracelular/metabolismo
Proteínas da Matriz Extracelular/metabolismo
Células HT29
Seres Humanos
Proteínas de Neoplasias/metabolismo
Dosagem Radioterapêutica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Extracellular Matrix Proteins); 0 (Neoplasm Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1667/RR14658.1



página 1 de 23 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde